presented the results of a Phase II RCT evaluating a Jak inhibitor with selectivity ... Treatment for rheumatoid arthritis (RA) has evolved over the last 15 years with early aggressive treatment ...

An international research team led by Geneva University Hospital found no increase in cardiovascular events during the first ...

Positive data in December from Rigel Pharmaceuticals' phase 2 trial of R788, an oral rheumatoid arthritis ... an inhibitor of a cytoplasmic (or 'non–membrane associated') tyrosine kinase ...

The use of JAK vs TNF inhibitors shows no significant increase in the incidence of major adverse cardiovascular events in ...

Eli Lilly has opted to end a phase 2 rheumatoid arthritis (RA ... to end phase 2 trials of its selective Bruton’s tyrosine kinase (BTK) inhibitor LY3337641/HM71224 in RA. Interim results ...

Pfizer has received approval from the US FDA for its rheumatoid arthritis (RA) drug, Xeljanz, which is the first approved RA treatment in a new class of medicines known as Janus kinase inhibitors ...

Disappointingly, a third drug also tested in the study failed to show additive efficacy in RA when combined with tofacitinib ...

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...

Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having ... pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

A Cleveland Clinic-led clinical trial of tolebrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, a group of drugs originally developed to treat lymphomas and related blood ...